Tag: PFE
Pfizer (PFE) Has Become Ridiculously Oversold
Investors may want to keep an eye on Pfizer (PFE).
The stock has become ridiculously oversold at double-bottom support dating back to late 2022. RSI, MACD,...
This is Why Pfizer is Still a Buy
Pfizer (PFE) has gone ballistic.
Since bottoming out at around $42 in October, the stock is now up to $53.33. From here, it could move...
Shares of Pfizer Just Got a Substantial Boost
There goes Pfizer (PFE).
The stock is popping on news it’s buying ReViral – a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and...
This is Why Pfizer Just Popped, As We Expected
Pfizer is pushing to higher highs.
In fact, as we noted on November 2, “After finding support around $41, the vaccine stock bolted to nearly...
This is Why Shares of Pfizer Could Race Higher
Pfizer is pushing to higher highs.
After finding support around $41, the vaccine stock bolted to nearly $46, and could test $47, even $50, near-term. ...
The Dogs of the Dow Didn’t Work Well in 2020, but...
One of the best ways to trade the New Year has been with the Dogs of the Dow.
This year, they weren’t so hot with...
The Top 3 Vaccine Trades that Should be in All Portfolios
Moderna (MRNA) has been incredibly explosive for us.
The first time we highlighted opportunity, the stock traded at $72 on Oct. 20. At the moment,...
This is Why Moderna Could Run to $200, Near-Term
Vaccine news has created big opportunity.
Look at BioNTech for example. The stock exploded from $88.50 to $124.24 after it and Pifzer said its vaccine had...
Top “Blood in the Streets” Opportunities to Consider
Over the last few months, the pandemic crippled the economy, destroying top stocks.
However, with a potential vaccine, those stocks may now be great “blood...
COVID-19 Vaccine: The Top Two Stocks to Consider Immediately
The pandemic is only getting worse.
At the moment, there are nearly 40 million global cases, with 1.1 million deaths. In the U.S., the count...
Popular Post
